UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________________

 

FORM 8-A

_________________________________

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) or (g) OF THE
SECURITIES EXCHANGE ACT OF 1934

_________________________________

 

Inhibikase Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_________________________________

 

Delaware

(State or other jurisdiction of incorporation or organization)

 

26-3407249

(I.R.S. Employer Identification No.)

 

3350 Riverwood Parkway SE, Suite 1900

Atlanta, Georgia

(Address of principal executive offices)

 

 

30339

(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be registered

 

Name of each exchange on which

each class is to be registered

Common Stock, $0.001 par value per share

 

 

The Nasdaq Stock Market LLC

 

_________________________________

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-240036

 

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 

 

 

 

Item 1. Description of Registrant's Securities to be Registered.

 

A description of the common stock, par value $0.001 per share, of Inhibikase Therapeutics, Inc., a Delaware corporation (the “Registrant”), to be registered hereunder is contained in the section titled “Description of Capital Stock” in the prospectus included in the Registrant’s Registration Statement on Form S-1 (File No. 333-240036), originally filed with the Securities and Exchange Commission (the “Commission”) on July 23, 2020, as subsequently amended from time to time (the “Registration Statement”), to which this Form 8-A relates, which is incorporated herein by reference. Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.

 

Item 2. Exhibits.

 

In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

Date:    October 29, 2020

 

 

INHIBIKASE THERAPEUTICS, INC.

 

By:       /s/ Milton H. Werner                                  

Milton H. Werner, Ph.D.

President and Chief Executive Officer